Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ribavirin plus interferon versus interferon for chronic hepatitis C.

J Brok1, L L Gluud, C Gluud

  • 1Centre for Clinical Intervention Research, Copenhagen University Hospital, Copenhagen Trial Unit, Department 7102, H:S Rigshospitalet, Blegdamsvej 9, Copenhagen, Denmark, 2100 Ø. jbrok@ctu.rh.dk

The Cochrane Database of Systematic Reviews
|July 22, 2005
PubMed
Summary

Ribavirin and interferon combination therapy effectively clears hepatitis C virus (HCV) and reduces liver disease progression. However, this combination therapy increases risks of anemia and other adverse events, potentially leading to treatment discontinuation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adherence to Protocol Recommendations for Children With Wilms Tumour in Two Consecutive Studies in the United Kingdom and Ireland-Does Variation Matter?

Pediatric blood & cancer·2026
Same author

Editorial: Dysfunctional Neutrophils in Cirrhosis With Acute Decompensation: Why It Matters.

Alimentary pharmacology & therapeutics·2025
Same author

The risks of adverse events with venlafaxine for adults with major depressive disorder: a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis.

Epidemiology and psychiatric sciences·2024
Same author

Assessment of metabolic dysfunction-associated steatotic liver disease in patients with hidradenitis suppurativa: A cross-sectional study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Tramadol for chronic pain in adults: protocol for a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.

Systematic reviews·2023
Same author

Risk factors associated with nausea and vomiting in children with cancer receiving chemotherapy.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2022

Area of Science:

  • Hepatology
  • Virology
  • Clinical Pharmacology

Background:

  • Hepatitis C virus (HCV) infection is a leading cause of liver disease, often progressing asymptomatically for decades.
  • Diagnosis typically relies on detecting HCV RNA and elevated transaminases.

Purpose of the Study:

  • To evaluate the efficacy and safety of combining ribavirin with interferon compared to interferon monotherapy for chronic hepatitis C.
  • Assessing beneficial effects on viral clearance and harmful effects, including adverse events.

Main Methods:

  • Systematic review and meta-analysis of 72 randomized controlled trials involving 9991 patients.
  • Primary outcomes included sustained virological response, liver-related morbidity, and all-cause mortality.
  • Analysis stratified by patient subgroups: naive, relapsers, and non-responders.

Related Experiment Videos

Main Results:

  • Combination therapy significantly improved sustained virological response across all subgroups (naive, relapsers, non-responders).
  • Ribavirin plus interferon reduced liver morbidity and mortality, and improved histological outcomes.
  • However, combination therapy substantially increased the risk of anemia (22% of patients) and other adverse events, leading to higher discontinuation rates.

Conclusions:

  • Ribavirin and interferon combination therapy is more effective than interferon alone for achieving sustained virological response and improving liver histology in chronic hepatitis C.
  • The enhanced efficacy may translate to reduced long-term morbidity and mortality.
  • Clinicians must weigh the significant benefits against the increased risk of adverse events, particularly anemia, when considering combination therapy.